Abbott Laboratories Valuation
| ABT Stock | USD 115.84 1.08 0.94% |
At this time, the firm appears to be undervalued. Abbott Laboratories shows a prevailing Real Value of $124.7 per share. The current price of the firm is $115.84. Our model approximates the value of Abbott Laboratories from analyzing the firm fundamentals such as profit margin of 0.15 %, and Return On Equity of 0.13 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Abbott Laboratories' valuation include:
Price Book 4.5775 | Enterprise Value | Enterprise Value Ebitda 20.5393 | Price Sales 4.4988 | Forward PE 23.3645 |
Undervalued
Today
Please note that Abbott Laboratories' price fluctuation is very steady at this time. Calculation of the real value of Abbott Laboratories is based on 3 months time horizon. Increasing Abbott Laboratories' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Abbott Laboratories' intrinsic value may or may not be the same as its current market price of 115.84, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 115.84 | Real 124.7 | Target 133.39 | Hype 114.99 | Naive 115.3 |
The intrinsic value of Abbott Laboratories' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Abbott Laboratories' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Abbott Laboratories helps investors to forecast how Abbott stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Abbott Laboratories more accurately as focusing exclusively on Abbott Laboratories' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Abbott Laboratories' intrinsic value based on its ongoing forecasts of Abbott Laboratories' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Abbott Laboratories' closest peers.
Abbott Laboratories Cash |
|
Abbott Revenue by Product
Abbott Laboratories Total Value Analysis
Abbott Laboratories is presently forecasted to have company total value of 237.62 B with market capitalization of 199.42 B, debt of 15.07 B, and cash on hands of 7.62 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Abbott Laboratories fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
237.62 B | 199.42 B | 15.07 B | 7.62 B |
Abbott Laboratories Investor Information
About 82.0% of the company shares are held by institutions such as insurance companies. The book value of Abbott Laboratories was presently reported as 30.02. The company last dividend was issued on the 15th of April 2026. Abbott Laboratories had 10000:4798 split on the 2nd of January 2013. Based on the key indicators related to Abbott Laboratories' liquidity, profitability, solvency, and operating efficiency, Abbott Laboratories may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.21 | 0.1816 |
|
| |||||
| Total Cash From Operating Activities | 5.4 B | 9.6 B |
|
| |||||
| Operating Income | 4.1 B | 8 B |
|
|
Abbott Laboratories Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Abbott Laboratories has an asset utilization ratio of 51.12 percent. This implies that the Company is making $0.51 for each dollar of assets. An increasing asset utilization means that Abbott Laboratories is more efficient with each dollar of assets it utilizes for everyday operations.Abbott Laboratories Profitability Analysis
Based on Abbott Laboratories' profitability indicators, Abbott Laboratories is performing exceptionally good at this time. It has a great probability to showcase excellent profitability results in March. Profitability indicators assess Abbott Laboratories' ability to earn profits and add value for shareholders.Net Income | First Reported 1985-09-30 | Previous Quarter 1.6 B | Current Value 1.8 B | Quarterly Volatility 866.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.59 | 0.5551 |
|
| |||||
| Net Profit Margin | 0.17 | 0.1472 |
|
| |||||
| Operating Profit Margin | 0.21 | 0.1816 |
|
| |||||
| Pretax Profit Margin | 0.21 | 0.191 |
|
| |||||
| Return On Assets | 0.12 | 0.0752 |
|
| |||||
| Return On Equity | 0.12 | 0.1251 |
|
|
For Abbott Laboratories profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Abbott Laboratories to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Abbott Laboratories utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Abbott Laboratories's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Abbott Laboratories over time as well as its relative position and ranking within its peers.
Abbott Laboratories Earnings per Share Projection vs Actual
The next projected EPS of Abbott Laboratories is estimated to be 1.15 with future projections ranging from a low of 1.1313 to a high of 1.21. Abbott Laboratories' most recent 12-month trailing earnings per share (EPS TTM) is at 3.72. Please be aware that the consensus of earnings estimates for Abbott Laboratories is based on EPS before non-recurring items and includes expenses related to employee stock options.Abbott Laboratories Earnings Estimation Breakdown
The calculation of Abbott Laboratories' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Abbott Laboratories is estimated to be 1.15 with the future projection ranging from a low of 1.1313 to a high of 1.21. Please be aware that this consensus of annual earnings estimates for Abbott Laboratories is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.13 Lowest | Expected EPS | 1.21 Highest |
Abbott Laboratories Earnings Projection Consensus
Suppose the current estimates of Abbott Laboratories' value are higher than the current market price of the Abbott Laboratories stock. In this case, investors may conclude that Abbott Laboratories is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Abbott Laboratories' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 29 | 95.51% | 1.5 | 1.15 | 3.72 |
Abbott Laboratories Ownership Allocation
Abbott Laboratories holds a total of 1.74 Billion outstanding shares. The majority of Abbott Laboratories outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Abbott Laboratories to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Abbott Laboratories. Please pay attention to any change in the institutional holdings of Abbott Laboratories as this could imply that something significant has changed or is about to change at the company. Please note that on January 16, 2026, Representative Julie Johnson of US Congress acquired under $15k worth of Abbott Laboratories's common stock.Abbott Laboratories Profitability Analysis
The company reported the last year's revenue of 44.33 B. Total Income to common stockholders was 6.52 B with profit before taxes, overhead, and interest of 25.12 B.Abbott Laboratories Past Distributions to stockholders
About Abbott Laboratories Valuation
The stock valuation mechanism determines Abbott Laboratories' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Abbott Laboratories based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Abbott Laboratories. We calculate exposure to Abbott Laboratories's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Abbott Laboratories's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 24.6 B | 12.3 B | |
| Pretax Profit Margin | 0.19 | 0.21 | |
| Operating Profit Margin | 0.18 | 0.21 | |
| Net Profit Margin | 0.15 | 0.17 | |
| Gross Profit Margin | 0.56 | 0.59 |
Abbott Laboratories Quarterly Retained Earnings |
|
A single share of Abbott Laboratories represents a small ownership stake in the entity. As a stockholder of Abbott, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Abbott Laboratories Dividends Analysis For Valuation
Dividend Paid And Capex Coverage Ratio is likely to gain to 1.88 in 2026, despite the fact that Dividends Paid is likely to grow to (3.9 B). . Retained Earnings is likely to gain to about 52.3 B in 2026, whereas Retained Earnings Total Equity is likely to drop slightly above 27.2 B in 2026.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | -4.1 B | -3.9 B | |
| Dividend Yield | 0.02 | 0.02 | |
| Dividend Payout Ratio | 0.63 | 0.45 | |
| Dividend Paid And Capex Coverage Ratio | 1.52 | 1.88 |
There are various types of dividends Abbott Laboratories can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Abbott shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Abbott Laboratories directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Abbott pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Abbott Laboratories by the value of the dividends paid out.
Abbott Laboratories Growth Indicators
Investing in growth stocks can be very risky. If the company such as Abbott Laboratories does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.7 B | |
| Quarterly Earnings Growth Y O Y | -0.809 | |
| Forward Price Earnings | 23.3645 |
Abbott Laboratories Current Valuation Indicators
Abbott Laboratories' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Abbott Laboratories' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Abbott Laboratories, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Abbott Laboratories' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Abbott Laboratories' worth.Additional Tools for Abbott Stock Analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.